Biosino Bio-Technology and Science Incorporation (HKG:8247)
Hong Kong · Delayed Price · Currency is HKD 3.480
+0.020 (0.58%)
At close: Apr 20, 2026
HKG:8247 Revenue
In the year 2025, Biosino Bio-Technology and Science Incorporation had annual revenue of 184.29M CNY, down -29.95%. Biosino Bio-Technology and Science Incorporation had revenue of 88.48M in the half year ending December 31, 2025, a decrease of -40.99%.
Revenue
184.29M CNY
Revenue Growth
-29.95%
P/S Ratio
2.46
Revenue / Employee
391.28K CNY
Employees
471
Market Cap
503.58M HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 184.29M | -78.78M | -29.95% |
| Dec 31, 2024 | 263.07M | -26.00M | -9.00% |
| Dec 31, 2023 | 289.07M | -84.00M | -22.52% |
| Dec 31, 2022 | 373.07M | 24.85M | 7.14% |
| Dec 31, 2021 | 348.23M | 22.97M | 7.06% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| WuXi XDC Cayman | 6.61B |
| Adicon Holdings | 2.94B |
| Kindstar Globalgene Technology | 1.04B |
| Yunkang Group | 669.23M |
| Mega Genomics | 275.03M |
| Guanze Medical Information Industry (Holding) | 98.42M |
| King International Investment | 77.50M |
| China Biotech Services Holdings | 73.50M |